- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
UCB SA (UCB)
Track the UCB share price today and view real-time UCB share price data, including charts, technicals, and key financials. View the UCB premarket stock price ahead of the market session or assess the after hours quote. Explore UCB stock price movements, trading volume, and market activity across the EBR exchange.
What Is the UCB Stock Price Today?
The UCB stock price today is 231.00.
What Is the Stock Symbol for UCB?
The stock symbol for UCB is ""UCB.""
What Stock Exchange Does UCB Trade On?
UCB is listed and trades on the Brussels stock exchange.
Is UCB a Good Stock to Buy?
Determining whether UCB or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UCB quote. (ISIN: BE0003739530)
What Is the UCB Stock Price Today?
The UCB stock price today is 231.00.
What Is the Stock Symbol for UCB?
The stock symbol for UCB is ""UCB.""
What Stock Exchange Does UCB Trade On?
UCB is listed and trades on the Brussels stock exchange.
Is UCB a Good Stock to Buy?
Determining whether UCB or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UCB quote. (ISIN: BE0003739530)
231.00
+2.50(+1.09%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
228.50
232.20
52 wk Range
146.05
289.50
UCB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
228.50232.20
52 wk Range
146.05289.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.44%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.44%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
UCB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
288.21
Upside
+24.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- UCB to acquire Candid Therapeutics for up to $2.2 billion
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- UCB to acquire Candid Therapeutics for up to $2.2 billion
- Investing.com
Pro - UCB to acquire Neurona Therapeutics for up to $1.15 billion
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
16 Buy
3 Hold
1 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 288.21
(+24.77% Upside)
Earnings
Latest Release
05/05/2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare UCB to Peers and Sector
Metrics to compare | UCB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUCBPeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.3x | 22.1x | −0.5x | |
PEG Ratio | 0.61 | 0.32 | 0.00 | |
Price/Book | 4.1x | 3.8x | 2.6x | |
Price / LTM Sales | 5.7x | 3.6x | 3.2x | |
Upside (Analyst Target) | 29.4% | 22.0% | 47.8% | |
Fair Value Upside | Unlock | 16.8% | 5.9% | Unlock |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the UCB (UCB) Stock Price Today?
The UCB stock price today is 231.00 EUR.
What Stock Exchange Does UCB Trade On?
UCB is listed and trades on the Brussels Stock Exchange.
What Is the Stock Symbol for UCB?
The stock symbol for UCB is "UCB."
Does UCB Pay Dividends? What’s The Current Dividend Yield?
The UCB dividend yield is 0.44%.
What Is the UCB Market Cap?
As of today, UCB market cap is 43.97B EUR.
What Is UCB's Earnings Per Share (TTM)?
The UCB EPS (TTM) is 8.03.
When Is the Next UCB Earnings Date?
UCB will release its next earnings report on 30/07/2026.
From a Technical Analysis Perspective, Is UCB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has UCB Stock Split?
UCB has split 1 times.
How Many Employees Does UCB Have?
UCB has 9765 employees.
What is the current trading status of UCB (UCB)?
As of 06/05/2026, UCB (UCB) is trading at a price of 231.00 EUR, with a previous close of 231.00 EUR. The stock has fluctuated within a day range of 228.50 EUR to 232.20 EUR, while its 52-week range spans from 146.05 EUR to 289.50 EUR.
What Is UCB (UCB) Price Target According to Analysts?
The average 12-month price target for UCB is 288.21 EUR, with a high estimate of 340 EUR and a low estimate of 195 EUR. 16 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +24.77% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.